Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358047 | 0.87 | GRM2 (0.46) | FFAR1GRM2MEN1LMNAMAPT | |
| SCHEMBL27711763 | 0.82 | HSP90AB1 (0.56) | MEN1LMNAMAPTHPGDHTT | |
| SCHEMBL30506519 | 0.79 | MEN1 (0.54) | FFAR1GRM2MEN1MAPTHTT | |
| SCHEMBL4937297 | 0.79 | MEN1 (0.54) | FFAR1GRM2MEN1MAPTHTT | |
| SCHEMBL4943475 | 0.78 | GRM2 (0.54) | FFAR1GRM2 | |
| SCHEMBL1831691 | 0.78 | FFAR1 (0.47) | FFAR1GRM2 | |
| SCHEMBL4945327 | 0.78 | FFAR1 (0.47) | FFAR1GRM2 | |
| SCHEMBL2009246 | 0.77 | ALDH1A1 (0.53) | MEN1LMNAMAPTHPGDHTT | |
| SCHEMBL31336021 | 0.77 | SELL (0.57) | MEN1MAPTHPGDHTTKMT2A | |
| SCHEMBL9874859 | 0.77 | SELL (0.57) | MEN1MAPTHPGDHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | FFAR1 149/4885BCL2L1 3971/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.